These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 15564232

  • 21. [When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent].
    MMW Fortschr Med; 2003 Dec 04; 145(49):18-9. PubMed ID: 14963986
    [No Abstract] [Full Text] [Related]

  • 22. Safety concerns of angiotensin II receptor blockers in preschool children.
    Tullus K.
    Arch Dis Child; 2011 Sep 04; 96(9):881-2. PubMed ID: 21690106
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
    He YL, Ligueros-Saylan M, Sunkara G, Sabo R, Zhao C, Wang Y, Campestrini J, Pommier F, Dole K, Marion A, Dole WP, Howard D.
    J Clin Pharmacol; 2008 Jan 04; 48(1):85-95. PubMed ID: 17986525
    [Abstract] [Full Text] [Related]

  • 26. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study.
    London G, Schmieder R, Calvo C, Asmar R.
    Am J Hypertens; 2006 Jan 04; 19(1):113-21. PubMed ID: 16461202
    [Abstract] [Full Text] [Related]

  • 27. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, Schneider H, Pospiech R.
    Clin Ther; 2007 Apr 04; 29(4):563-80. PubMed ID: 17617280
    [Abstract] [Full Text] [Related]

  • 28. Amlodipine + valsartan + hydrochlorothiazide. A 3-drug fixed-dose combination for hypertension: too many drawbacks.
    Prescrire Int; 2011 Mar 04; 20(114):67. PubMed ID: 21648225
    [No Abstract] [Full Text] [Related]

  • 29. Valsartan-induced drug eruption followed by CD30+ pseudolymphomatous eruption.
    Sawada Y, Yoshiki R, Kawakami C, Fukamachi S, Sugita K, Nakamura M, Tokura Y.
    Acta Derm Venereol; 2010 Sep 04; 90(5):521-2. PubMed ID: 20814632
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Angiotensin receptor blockers: baseline therapy in hypertension?
    Messerli FH, Bangalore S, Ruschitzka F.
    Eur Heart J; 2009 Oct 04; 30(20):2427-30. PubMed ID: 19723696
    [No Abstract] [Full Text] [Related]

  • 32. [Cross reactivity between ACE inhibitors and angiotensin receptor blockers].
    Rosenborg S.
    Lakartidningen; 2009 Oct 04; 107(7):444. PubMed ID: 20384078
    [No Abstract] [Full Text] [Related]

  • 33. [Successful mega studies with heart patients. Valsartan possesses cardioprotective action].
    MMW Fortschr Med; 2006 Feb 02; 148(5):48-9. PubMed ID: 16518941
    [No Abstract] [Full Text] [Related]

  • 34. Valsartan, captopril, or both in myocardial infarction.
    Jorde UP.
    N Engl J Med; 2004 Feb 26; 350(9):943-5; author reply 943-5. PubMed ID: 14988936
    [No Abstract] [Full Text] [Related]

  • 35. Valsartan, captopril, or both in myocardial infarction.
    Moshenyat R, Kupfer Y, Tessler S.
    N Engl J Med; 2004 Feb 26; 350(9):943-5; author reply 943-5. PubMed ID: 14988935
    [No Abstract] [Full Text] [Related]

  • 36. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.
    Corea L, Cardoni O, Fogari R, Innocenti P, Porcellati C, Provvidenza M, Meilenbrock S, Sullivan J, Bodin F.
    Clin Pharmacol Ther; 1996 Sep 26; 60(3):341-6. PubMed ID: 8841157
    [Abstract] [Full Text] [Related]

  • 37. Warnings against candesartan in pregnancy are not implemented in physicians' practice.
    Borthen C, Oglaend B, Eggebøe T, Ellingsen CL, Schjøtt J.
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct 26; 146(2):235. PubMed ID: 19615811
    [No Abstract] [Full Text] [Related]

  • 38. Increased renal echogenicity in a preterm neonate. Kidneys with tubular dysplasia due to exposure to candesartan during pregnancy.
    Bald M, Holder M, Zieger M, Vochem M, Leichter HE.
    Pediatr Nephrol; 2005 Nov 26; 20(11):1664-5, 1666-8. PubMed ID: 16082550
    [No Abstract] [Full Text] [Related]

  • 39. [Risk oriented therapy of hypertension. Lowering blood pressure and risk].
    MMW Fortschr Med; 2007 Nov 15; 149(46):53. PubMed ID: 18069196
    [No Abstract] [Full Text] [Related]

  • 40. Valsartan-induced angioedema in a patient on angiotensin-converting enzyme inhibitor for years: case report and literature review.
    Kalra A, Cooley C, Palaniswamy C, Kalra A, Zanotti-Cavazzoni SL.
    Am J Ther; 2012 Nov 15; 19(6):e189-92. PubMed ID: 20838200
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.